End-stage heart failure in congenitally corrected transposition of the great arteries: a multicentre study.


Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
07 09 2023
Historique:
received: 24 11 2022
revised: 19 05 2023
accepted: 25 07 2023
medline: 8 9 2023
pubmed: 18 8 2023
entrez: 18 8 2023
Statut: ppublish

Résumé

For patients with congenitally corrected transposition of the great arteries (ccTGA), factors associated with progression to end-stage congestive heart failure (CHF) remain largely unclear. This multicentre, retrospective cohort study included adults with ccTGA seen at a congenital heart disease centre. Clinical data from initial and most recent visits were obtained. The composite primary outcome was mechanical circulatory support, heart transplantation, or death. From 558 patients (48% female, age at first visit 36 ± 14.2 years, median follow-up 8.7 years), the event rate of the primary outcome was 15.4 per 1000 person-years (11 mechanical circulatory support implantations, 12 transplantations, and 52 deaths). Patients experiencing the primary outcome were older and more likely to have a history of atrial arrhythmia. The primary outcome was highest in those with both moderate/severe right ventricular (RV) dysfunction and tricuspid regurgitation (n = 110, 31 events) and uncommon in those with mild/less RV dysfunction and tricuspid regurgitation (n = 181, 13 events, P < .001). Outcomes were not different based on anatomic complexity and history of tricuspid valve surgery or of subpulmonic obstruction. New CHF admission or ventricular arrhythmia was associated with the primary outcome. Individuals who underwent childhood surgery had more adverse outcomes than age- and sex-matched controls. Multivariable Cox regression analysis identified older age, prior CHF admission, and severe RV dysfunction as independent predictors for the primary outcome. Patients with ccTGA have variable deterioration to end-stage heart failure or death over time, commonly between their fifth and sixth decades. Predictors include arrhythmic and CHF events and severe RV dysfunction but not anatomy or need for tricuspid valve surgery.

Sections du résumé

BACKGROUND AND AIMS
For patients with congenitally corrected transposition of the great arteries (ccTGA), factors associated with progression to end-stage congestive heart failure (CHF) remain largely unclear.
METHODS
This multicentre, retrospective cohort study included adults with ccTGA seen at a congenital heart disease centre. Clinical data from initial and most recent visits were obtained. The composite primary outcome was mechanical circulatory support, heart transplantation, or death.
RESULTS
From 558 patients (48% female, age at first visit 36 ± 14.2 years, median follow-up 8.7 years), the event rate of the primary outcome was 15.4 per 1000 person-years (11 mechanical circulatory support implantations, 12 transplantations, and 52 deaths). Patients experiencing the primary outcome were older and more likely to have a history of atrial arrhythmia. The primary outcome was highest in those with both moderate/severe right ventricular (RV) dysfunction and tricuspid regurgitation (n = 110, 31 events) and uncommon in those with mild/less RV dysfunction and tricuspid regurgitation (n = 181, 13 events, P < .001). Outcomes were not different based on anatomic complexity and history of tricuspid valve surgery or of subpulmonic obstruction. New CHF admission or ventricular arrhythmia was associated with the primary outcome. Individuals who underwent childhood surgery had more adverse outcomes than age- and sex-matched controls. Multivariable Cox regression analysis identified older age, prior CHF admission, and severe RV dysfunction as independent predictors for the primary outcome.
CONCLUSIONS
Patients with ccTGA have variable deterioration to end-stage heart failure or death over time, commonly between their fifth and sixth decades. Predictors include arrhythmic and CHF events and severe RV dysfunction but not anatomy or need for tricuspid valve surgery.

Identifiants

pubmed: 37592821
pii: 7244786
doi: 10.1093/eurheartj/ehad511
pmc: PMC10482567
doi:

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

3278-3291

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.

Références

Circulation. 2016 Feb 23;133(8):770-801
pubmed: 26787728
Am Rev Respir Dis. 1984 Feb;129(2 Pt 2):S49-55
pubmed: 6421218
Int J Cardiol. 2014 Feb 1;171(2):184-91
pubmed: 24374205
Chest. 1992 May;101(5):1382-5
pubmed: 1582301
J Thorac Cardiovasc Surg. 1995 Apr;109(4):642-52; discussion 652-3
pubmed: 7715211
Int J Cardiol. 2018 May 1;258:83-89
pubmed: 29463466
Int J Cardiol. 2015 Oct 1;196:1-6
pubmed: 26070176
Circulation. 1998 Sep 8;98(10):997-1005
pubmed: 9737520
J Am Coll Cardiol. 2016 Aug 30;68(9):908-17
pubmed: 27561764
Circulation. 2019 Apr 2;139(14):e801-e813
pubmed: 30586770
Hellenic J Cardiol. 2005 Sep-Oct;46(5):370-3
pubmed: 16295949
JACC Cardiovasc Imaging. 2022 Apr;15(4):566-574
pubmed: 34801447
J Am Coll Cardiol. 2019 Apr 2;73(12):1494-1563
pubmed: 30121240
J Heart Lung Transplant. 2018 Jan;37(1):89-99
pubmed: 28365175
J Am Coll Cardiol. 2000 Jul;36(1):255-61
pubmed: 10898443
Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2019;22:66-73
pubmed: 31027567
Eur Heart J Cardiovasc Imaging. 2022 Apr 18;23(5):680-688
pubmed: 34059878
Open Heart. 2016 Jul 11;3(2):e000407
pubmed: 27493760
J Heart Lung Transplant. 2013 Nov;32(11):1059-64
pubmed: 23921356
Am Heart J. 1989 Sep;118(3):526-30
pubmed: 2773773
Eur Heart J. 2022 Jul 21;43(28):2685-2694
pubmed: 35673927
J Am Coll Cardiol. 2022 Sep 6;80(10):951-963
pubmed: 36049802
J Am Coll Cardiol. 2011 May 17;57(20):2008-17
pubmed: 21565637
Eur Heart J. 2021 Feb 11;42(6):563-645
pubmed: 32860028

Auteurs

Alexandra C van Dissel (AC)

Department of Clinical and Experimental Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Knight Cardiovascular Institute, Oregon Health and Science University, 3181 SW Sam Jackson Pk Rd, Portland, OR 97221, USA.

Alexander R Opotowsky (AR)

Department of Paediatrics, Cincinnati Children's Hospital Medical Centre, Heart Institute, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Luke J Burchill (LJ)

Department of Medicine, Royal Melbourne Hospital, Melbourne, Australia.

Jamil Aboulhosn (J)

Ronald Regan/UCLA Medical Centre, Los Angeles, CA, USA.

Jasmine Grewal (J)

Division of Cardiology, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.

Adam M Lubert (AM)

Department of Paediatrics, Cincinnati Children's Hospital Medical Centre, Heart Institute, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Petra Antonova (P)

University Hospital Motol, Prague, Czech Republic.

Sangeeta Shah (S)

Ochsner Medical Centre, New Orleans, LA, USA.

Timothy Cotts (T)

University of Michigan Medical Centre, Ann Arbor, MI, USA.

Anitha S John (AS)

Children's National Hospital, Washington, DC, USA.

William Aaron Kay (WA)

Mercy Heart Institute, Cincinnati, OH, USA.

Christopher DeZorzi (C)

University of Missouri-Kansas City and Saint Luke's Hospital, Kansas City, MO, USA.

Anthony Magalski (A)

University of Missouri-Kansas City and Saint Luke's Hospital, Kansas City, MO, USA.

Frank Han (F)

University of Illinois, Chicago, IL, USA.

David Baker (D)

The University of Sydney and Royal Prince Alfred Hospital, Sydney, Australia.

Joseph Kay (J)

Colorado University School of Medicine, Denver, CO, USA.

Elizabeth Yeung (E)

Colorado University School of Medicine, Denver, CO, USA.

Isabelle Vonder Muhll (I)

University of Alberta, Edmonton, AB, Canada.

Stephen Pylypchuk (S)

University of Alberta, Edmonton, AB, Canada.

Marissa C Kuo (MC)

Emory University School of Medicine, Atlanta, GA, USA.

Jeremy Nicolarsen (J)

Providence Spokane, Spokane, WA, USA.

Berardo Sarubbi (B)

Monaldi Hospital, Napoli, Italy.

Flavia Fusco (F)

Monaldi Hospital, Napoli, Italy.

Susan M Jameson (SM)

Departments of Paediatrics and Cardiovascular Medicine, School of Medicine, Stanford University, Palo Alto, CA, USA.

Jonathan Cramer (J)

Children's Hospital, University of Nebraska Medical Centre, Omaha, NE, USA.

Tripti Gupta (T)

Ochsner Medical Centre, New Orleans, LA, USA.

Pastora Gallego (P)

Hospital Universitario Virgen Del Rocio, Sevilla, Spain.
European Reference Network for Rare, Low Prevalence and Complex Disease of the Heart-ERN GUARD Heart.

Clare O'Donnell (C)

Green Lane Paediatric and Congenital Cardiac Service, Auckland City Hospital, Auckland, New Zealand.

Jane Hannah (J)

Green Lane Paediatric and Congenital Cardiac Service, Auckland City Hospital, Auckland, New Zealand.

Mikael Dellborg (M)

Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Robert M Kauling (RM)

Erasmus Medical Centre, Rotterdam, The Netherlands.

Salil Ginde (S)

Children's Hospital of Wisconsin, Milwaukee, WI, USA.

Eric V Krieger (EV)

University of Washington Medical Centre and Seattle Children's Hospital, Seattle, WA, USA.

Fred Rodriguez (F)

Emory University School of Medicine, Atlanta, GA, USA.

Payam Dehghani (P)

Regina General Hospital, Regina, Canada.

Shelby Kutty (S)

Johns Hopkins University, Baltimore, MD, USA.

Joshua Wong (J)

Department of Medicine, Royal Melbourne Hospital, Melbourne, Australia.

William M Wilson (WM)

Department of Medicine, Royal Melbourne Hospital, Melbourne, Australia.

Carla P Rodriguez-Monserrate (CP)

Harvard Medical School, Boston Children's Hospital, Boston, MA, USA.

Jolien Roos-Hesselink (J)

European Reference Network for Rare, Low Prevalence and Complex Disease of the Heart-ERN GUARD Heart.
Erasmus Medical Centre, Rotterdam, The Netherlands.

David S Celermajer (DS)

The University of Sydney and Royal Prince Alfred Hospital, Sydney, Australia.

Paul Khairy (P)

Montreal Heart Institute, Université de Montréal, Montreal, Canada.

Craig S Broberg (CS)

Knight Cardiovascular Institute, Oregon Health and Science University, 3181 SW Sam Jackson Pk Rd, Portland, OR 97221, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH